{"id":"NCT00232141","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With HIV Neuropathy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2005-10-04","resultsPosted":"2009-08-11","lastUpdate":"2021-02-09"},"enrollment":302,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections","Peripheral Neuropathy"],"interventions":[{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"Study to determine if pregabalin is more effective than placebo in treating subjects with nerve pain associated with HIV neuropathy.","primaryOutcome":{"measure":"Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline","timeFrame":"Baseline, Week 14","effectByArm":[{"arm":"Pregabalin","deltaMin":-2.88,"sd":0.21},{"arm":"Placebo","deltaMin":-2.63,"sd":0.21}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3914"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":44,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081066&StudyName=Study%20of%20Pregabalin%20versus%20placebo%20in%20the%20treatment%20of%20Nerve%20Pain%20associated%20with%20HIV%20Neuropathy%20"]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}